Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
The Obesity Revolution
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

By Chris MorrisonNov. 18, 2019

Reprints
Vascepa pill handout
Amarin

PHILADELPHIA — Dr. Matthew Budoff probably didn’t want to bury the lede.

On Monday, the UCLA School of Medicine professor was at the annual meeting of the American Heart Association, diving into a news conference on data from an imaging study to investigate the effects of Amarin’s fish oil-derived drug Vascepa on harmful plaque growth in statin-treated patients. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Chris Morrison

Tags

There is no epidemic of autism. It’s an epidemic…
There is no epidemic of autism. It’s an epidemic of need
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s…
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
The lesson biotech absolutely should not take from Silicon…
The lesson biotech absolutely should not take from Silicon Valley Bank’s failure

Recommended Stories